Answers are grounded in this paper and cite their sources.
Serotonergic (5-HT) neurons degenerate in Parkinson’s disease. To determine the role of this 5-HT injury—besides the dopaminergic one in the parkinsonian symptomatology—we developed a new monkey model exhibiting a double dopaminergic/serotonergic lesion by sequentially using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 3,4-methylenedioxy-N-methamphetamine (MDMA, better known as ecstasy). By positron emission tomography imaging and immunohistochemistry, we demonstrated that MDMA injured 5-HT nerve terminals in the brain of MPTP monkeys. Unexpectedly, this injury had no impact on tremor or on bradykinesia, but altered rigidity. It abolished the l-DOPA-induced dyskinesia and neuropsychiatric-like behaviours, without altering the anti-parkinsonian response. These data demonstrate that 5-HT fibres play a critical role in the expression of both motor and non-motor symptoms in Parkinson’s disease, and highlight that an imbalance between the 5-HT and dopaminergic innervating systems is involved in specific basal ganglia territories for different symptoms. To determine the role of serotonergic degeneration in Parkinson’s disease, Beaudoin-Gobert et al. use sequential MPTP and MDMA to produce a monkey model with a double dopaminergic/serotonergic lesion. Damage to serotonin fibres has no effect on tremor or bradykinesia, but alters rigidity and abolishes L-DOPA-induced dyskinesias and neuropsychiatric symptoms.
No takes yet. Share an insight, caveat, or question.
Beaudoin‐Gobert et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: